For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell field. In CML, the acquisition of the fusion tyrosine kinase BCR–ABL1 in a haematopoietic stem cell drives its transformation to become a LSC. In AML, LSCs can arise from multiple cell types through the activity of a number of oncogenic drivers and pre-leukaemic events, adding further layers of context and genetic and cellular heterogeneity to AML LSCs not observed in most cases of CML. Furthermore, LSCs from both AML and CML can be refractory to standard-of-care therapies and persist in patients, diversify clonally and serve as reservoirs to drive relapse, recurrence or progression to more aggressive forms. Despite these complexities, LSCs in both diseases share biological features, making them distinct from other CML or AML progenitor cells and from normal haematopoietic stem cells. These features may represent Achilles’ heels against which novel therapies can be developed. Here, we review many of the similarities and differences that exist between LSCs in CML and AML and examine the therapeutic strategies that could be used to eradicate them.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Nowell, P. C. & Hungerford, D. A. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J. Natl Cancer Inst. 27, 1013–1035 (1961).
Rowley, J. D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290–293 (1973).
Heisterkamp, N. et al. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 306, 239–242 (1983).
Hehlmann, R. How I treat CML blast crisis. Blood 120, 737–747 (2012).
Cortes, J. E. et al. Final 5-year study results of DASISION: the Dasatinib versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. J. Clin. Oncol. 34, 2333–2340 (2016).
Hochhaus, A. et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30, 1044–1054 (2016).
Hochhaus, A. et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N. Engl. J. Med. 376, 917–927 (2017). This study highlights the safety and clinical benefit of long-term imatinib treatment for patients with CML based on more than 10 years of follow-up.
Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029–1035 (2010). This was the first study to demonstrate that a minority of patients with CML can safely discontinue long-term TKI therapy and achieve TFR.
Ross, D. M. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122, 515–522 (2013).
Huang, X., Cortes, J. & Kantarjian, H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118, 3123–3127 (2012).
Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209–2221 (2016).
Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391–2405 (2016).
Short, N.J., Kantarjian, H., Ravandi, F. & Daver, N. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther. Adv. Hematol. 10, 2040620719827310 (2019).
Wei, A. H. & Tiong, I. S. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood 130, 2469–2474 (2017).
Daver, N., Schlenk, R. F., Russell, N. H. & Levis, M. J. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33, 299–312 (2019).
Medeiros, B. C., Chan, S. M., Daver, N. G., Jonas, B. A. & Pollyea, D. A. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am. J. Hematol. 94, 803–811 (2019).
Levin, R. H. et al. Persistent mitosis of transfused homologous leukocytes in children receiving antileukemic therapy. Science 142, 1305–1311 (1963).
Clarkson, B., Ohkita, T., Ota, K. & Fried, J. Studies of cellular proliferation in human leukemia. I. Estimation of growth rates of leukemic and normal hematopoietic cells in two adults with acute leukemia given single injections of tritiated thymidine. J. Clin. Invest. 46, 506–529 (1967).
Fialkow, P. J. The origin and development of human tumors studied with cell markers. N. Engl. J. Med. 291, 26–35 (1974).
Griffin, J. D. & Lowenberg, B. Clonogenic cells in acute myeloblastic leukemia. Blood 68, 1185–1195 (1986).
Lapidot, T. et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 367, 645–648 (1994).
Holyoake, T., Jiang, X., Eaves, C. & Eaves, A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94, 2056–2064 (1999).
Ishikawa, F. et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 25, 1315–1321 (2007).
Chu, S. et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 118, 5565–5572 (2011).
Chomel, J. C. et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 118, 3657–3660 (2011).
Bhatia, R. et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701–4707 (2003).
Jordan, C. T., Guzman, M. L. & Noble, M. Cancer stem cells. N. Engl. J. Med. 355, 1253–1261 (2006).
Farge, T. et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 7, 716–735 (2017). This paper describes the metabolic state of the leukaemic cells that survive chemotherapy in mouse models and challenges the long-held view that chemotherapy does not target LSCs.
Boyd, A. L. et al. Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of human AML recurrence. Cancer Cell 34, 483–498 (2018). This paper describes how the leukaemic cells that survive chemotherapy in mouse models and in patients are different from LSCs and have transient molecular features that are targetable.
Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737 (1997).
Lemoli, R. M. et al. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34– cell population with intrinsic resistance to imatinib. Blood 114, 5191–5200 (2009).
Jamieson, C. H. M. et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657–667 (2004).
Kinstrie, R. et al. Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. Blood Adv. 1, 160–169 (2016).
Tanizaki, R. et al. Irrespective of CD34 expression, lineage-committed cell fraction reconstitutes and re-establishes transformed Philadelphia chromosome-positive leukemia in NOD/SCID/IL-2Rγc-/- mice. Cancer Sci. 101, 631–638 (2010).
Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17, 1086–1093 (2011). This paper describes how LSC functional assays, when combined with global transcriptome profiling, can be used to identify stem cell mRNA signatures that are linked to prognosis.
Goardon, N. et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19, 138–152 (2011).
Quek, L. et al. Genetically distinct leukemic stem cells in human CD34– acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J. Exper. Med. 213, 1513–1535 (2016).
Somervaille, T. C. P. & Cleary, M. L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10, 257–268 (2006).
Kirstetter, P. et al. Modeling of C/EBPα mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell 13, 299–310 (2008).
Somervaille, T. C. P. et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 4, 129–140 (2009).
Ailles, L. E., Gerhard, B. & Hogge, D. E. Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood 90, 2555–2564 (1997).
Udomsakdi, C. et al. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc. Natl Acad. Sci. USA 89, 6192–6196 (1992).
Dick, J. E. Stem cell concepts renew cancer research. Blood 112, 4793–4807 (2008).
Reinisch, A. et al. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nat. Med. 22, 812–821 (2016).
Griessinger, E. et al. Acute myeloid leukemia xenograft success prediction: saving time. Exp. Hematol. 59, 66–71 (2018).
Pearce, D. J. et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 107, 1166–1173 (2006).
Ran, D. et al. Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp. Hematol. 37, 1423–1434 (2009).
Hope, K. J., Jin, L. Q. & Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 5, 738–743 (2004).
Vargaftig, J. et al. Frequency of leukemic initiating cells does not depend on the xenotransplantation model used. Leukemia 26, 858–860 (2012).
Wunderlich, M. et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24, 1785–1788 (2010).
Cosgun, K. N. et al. Kit regulates HSC engraftment across the human-mouse species barrier. Cell Stem Cell 15, 227–238 (2014).
McIntosh, B. E. et al. Nonirradiated NOD,B6.SCID Il2rγ -/- Kit W41/W41 (NBSGW) mice support multilineage engraftment of human hematopoietic cells. Stem Cell Rep. 4, 171–180 (2015).
Miller, P. H. et al. Analysis of parameters that affect human hematopoietic cell outputs in mutant c-kit-immunodeficient mice. Exp. Hematol. 48, 41–49 (2017).
Krevvata, M. et al. Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells. Haematologica 103, 959–971 (2018).
Klco, J. M. et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 25, 379–392 (2014).
Nakamichi, N. et al. Enhanced and accelerated repopulation of mutant c-kit immunodeficient mice by transplants of primary chronic and acute myeloid leukemic human cells. Blood 128, 4537–4537 (2016).
Gerber, J. M. et al. Characterization of chronic myeloid leukemia stem cells. Am. J. Hematol. 86, 31–37 (2011).
Koschmieder, S. et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 105, 324–334 (2005).
Zhang, B. et al. Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells. J. Clin. Invest. 126, 975–991 (2016).
Guan, Y., Gerhard, B. & Hogge, D. E. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 101, 3142–3149 (2003).
Terpstra, W. et al. Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. Blood 88, 1944–1950 (1996).
Lechman, E. R. et al. miR-126 regulates distinct self-renewal outcomes in normal and malignant hematopoietic stem cells. Cancer Cell 29, 214–228 (2016).
Prost, S. et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature 525, 380–383 (2015). This study describes how the re-purposed clinical agent pioglitazone, when combined with TKIs, eradicates quiescent CML LSCs by targeting the PPARγ–STAT5–HIF2α–CITED2 pathway.
Iwasaki, M., Liedtke, M., Gentles, A. J. & Cleary, M. L. CD93 marks a non-quiescent human leukemia stem cell population and is required for development of MLL-rearranged acute myeloid leukemia. Cell Stem Cell 17, 412–421 (2015).
Saito, Y. et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 28, 275–280 (2010).
Baquero, P. et al. Targeting quiescent leukemic stem cells using second generation autophagy inhibitors. Leukemia 33, 981–994 (2019).
Nieborowska-Skorska, M. et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 119, 4253–4263 (2012).
Sallmyr, A. et al. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood 111, 3173–3182 (2008).
Adane, B. et al. The hematopoietic oxidase NOX2 regulates self-renewal of leukemic stem cells. Cell Rep. 27, 238–254 (2019).
Moloney, J. N., Stanicka, J. & Cotter, T. G. Subcellular localization of the FLT3-ITD oncogene plays a significant role in the production of NOX- and p22(phox)-derived reactive oxygen species in acute myeloid leukemia. Leuk. Res. 52, 34–42 (2017).
Kuntz, E. M. et al. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat. Med. 23, 1234–1240 (2017). This paper demonstrates that CML LSCs are metabolically distinct from normal HSCs and rely on upregulated OXPHOS for their survival.
Skrtic, M. et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20, 674–688 (2011).
Ito, K. et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat. Med. 12, 446–451 (2006).
Bolton-Gillespie, E. et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 121, 4175–4183 (2013).
Lagadinou, E. D. et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329–341 (2013).
Pei, S. et al. AMPK/FIS1-mediated mitophagy is required for self-renewal of human AML stem cells. Cell Stem Cell 23, 86–100 (2018).
Hao, X. X. et al. Metabolic imaging reveals a unique preference of symmetric cell division and homing of leukemia-initiating cells in an endosteal niche. Cell Metab. 29, 950–965 (2019). This study describes a new method using in vivo imaging, which defines the molecular features and localization of AML LSCs in the bone marrow niche.
Grossmann, V. et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 25, 557–560 (2011).
Rebechi, M. T. & Pratz, K. W. Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression. Leuk. Lymphoma 58, 2040–2050 (2017).
Cramer, K. et al. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res. 68, 6884–6888 (2008).
Stoklosa, T. et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res. 68, 2576–2580 (2008).
Cramer-Morales, K. et al. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood 122, 1293–1304 (2013).
Holyoake, T. L. & Vetrie, D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood 129, 1595–1606 (2017).
Pearsall, E. A., Lincz, L. F. & Skelding, K. A. The role of DNA repair pathways in AML chemosensitivity. Curr. Drug Targets 19, 1205–1219 (2018).
Ho, T. C. et al. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood 128, 1671–1678 (2016).
Kumari, A., Brendel, C., Hochhaus, A., Neubauer, A. & Burchert, A. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 119, 530–539 (2012).
Ng, S. W. K. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433–437 (2016).
Jung, N., Dai, B., Gentles, A. J., Majeti, R. & Feinberg, A. P. An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis. Nat. Commun. 6, 8489 (2015).
Krivtsov, A. V. et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia 27, 852–860 (2013).
Laverdiere, I. et al. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia. Blood Cancer J. 8, 52 (2018).
Graham, S. M., Vass, J. K., Holyoake, T. L. & Graham, G. J. Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 25, 3111–3120 (2007).
Abraham, S. A. et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature 534, 341–346 (2016). Using an unbiased systems biology approach, this paper describes the identification of p53 and MYC as critical regulators of CML LSC survival.
Scott, M. T. et al. Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discov. 6, 1248–1257 (2016). This study demonstrates that EZH2 and the histone modification H3K27me3 are dysregulated in CP-CML, thus making LSCs sensitive to EZH2 inhibition.
Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474–478 (2012).
Corces, M. R. et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat. Genet. 48, 1193–1203 (2016).
Jan, M. et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med. 4, 149ra118 (2012).
Shlush, L. I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328–333 (2014).
Gilliland, D. G. & Griffin, J. D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100, 1532–1542 (2002).
Zheng, R. & Small, D. Mutant FLT3 signaling contributes to a block in myeloid differentiation. Leuk. Lymphoma 46, 1679–1687 (2005).
Lal, R. et al. Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. Blood 129, 2587–2591 (2017).
Cancer Genome Atlas Research Network. et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013).
Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014).
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
Schmidt, M. et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia 28, 2292–2299 (2014).
Kim, T. et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood 129, 38–47 (2017).
Branford, S. et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood 132, 948–961 (2018).
Huntly, B. J. et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587–596 (2004).
George, J. et al. Leukaemia cell of origin identified by chromatin landscape of bulk tumour cells. Nat. Commun. 7, 12166 (2016).
Gunsilius, E. et al. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 355, 1688–1691 (2000).
Foley, S. B. et al. Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia. Cell Rep. 5, 51–60 (2013).
Cheung, A. M. et al. Analysis of the clonal growth and differentiation dynamics of primitive barcoded human cord blood cells in NSG mice. Blood 122, 3129–3137 (2013).
Biernaux, C., Loos, M., Sels, A., Huez, G. & Stryckmans, P. Detection of major Bcr-Abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86, 3118–3122 (1995).
Easwaran, H., Tsai, H. C. & Baylin, S. B. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell 54, 716–727 (2014).
Flavahan, W. A., Gaskell, E. & Bernstein, B. E. Epigenetic plasticity and the hallmarks of cancer. Science 357, eaal2380 (2017).
Corces-Zimmerman, M. R., Hong, W. J., Weissman, I. L., Medeiros, B. C. & Majeti, R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl Acad. Sci. USA 111, 2548–2553 (2014).
Rothenberg-Thurley, M. et al. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia 32, 1598–1608 (2018).
Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319–325 (2002).
Jorgensen, H. G., Allan, E. K., Jordanides, N. E., Mountford, J. C. & Holyoake, T. L. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109, 4016–4019 (2007).
Warfvinge, R. et al. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood 129, 2384–2394 (2017).
Giustacchini, A. et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat. Med. 23, 692–702 (2017). This study utilizes single-cell transcriptomics to characterize LSCs in patients with CML and identifies the mRNA signatures of LSCs that persist during TKI therapy.
Corbin, A. S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396–409 (2011). This paper details how CML LSCs are not oncogene addicted, thus allowing them to survive in the absence of BCR–ABL1 kinase activity.
Hamilton, A. et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119, 1501–1510 (2012).
Shlush, L. I. et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature 547, 104–108 (2017). This paper describes the genetic and functional approaches used to determine the clonal evolution of chemotherapy-resistant LSCs that drive relapse in AML.
Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506–510 (2012).
Yilmaz, M. et al. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 9, 7 (2019).
Soverini, S., de Benedittis, C., Mancini, M. & Martinelli, G. Mutations in the BCR-ABL1 kinase domain and elsewhere in chronic myeloid leukemia. Clin. Lymphoma Myeloma Leuk. 15(Suppl.), S120–S128 (2015).
Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117–125 (2002).
Franke, G.N. et al. Incidence of low level mutations in newly diagnosed CML patients: a substudy of the German Tiger Trial. Blood 130, 252 (2017).
Bumm, T. et al. Emergence of clonal cytogenetic abnormalities in Ph− cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101, 1941–1949 (2003).
De Melo, V. A. S. et al. Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia. Blood 110, 3086–3087 (2007).
Shih, A. H. et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell 27, 502–515 (2015).
Wong, S. H. K. et al. The H3K4-methyl epigenome regulates leukemia stem cell oncogenic potential. Cancer Cell 28, 198–209 (2015).
Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66–78 (2011).
Li, S. et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat. Med. 22, 792–799 (2016).
Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010).
Glass, J. L. et al. Epigenetic identity in AML depends on disruption of nonpromoter regulatory elements and is affected by antagonistic effects of mutations in epigenetic modifiers. Cancer Discov. 7, 868–883 (2017).
Figueroa, M. E. et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13–27 (2010).
Will, B. et al. Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia. Nat. Med. 21, 1172–1181 (2015).
Assi, S. A. et al. Subtype-specific regulatory network rewiring in acute myeloid leukemia. Nat. Genet. 51, 151–162 (2019). This paper demonstrates how global chromatin and transcriptional profiling can be used to assemble gene regulatory networks in AML subtypes.
Harris, W. J. et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21, 473–487 (2012).
Basheer, F. et al. Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. J. Exp. Med. 216, 966–981 (2019).
Li, L. et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21, 266–281 (2012). This study describes how the deacetylase SIRT1 plays a critical role in regulating p53 activity in CML LSCs to promote their survival.
Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524–528 (2011).
Koschmieder, S. & Vetrie, D. Epigenetic dysregulation in chronic myeloid leukaemia: a myriad of mechanisms and therapeutic options. Semin. Cancer Biol. 51, 180–197 (2018).
Deshpande, A. J. et al. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell 26, 896–908 (2014).
Riether, C. et al. Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. Sci. Transl. Med. 7, 298ra119 (2015).
Jin, Y. et al. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J. Clin. Invest. 126, 3961–3980 (2016).
Abraham, A. et al. SIRT1 regulates metabolism and leukemogenic potential in CML stem cells. J. Clin. Invest. 129, 2685–2701 (2019).
Fong, C. Y. et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525, 538–542 (2015).
Reid, M. A., Dai, Z. W. & Locasale, J. W. The impact of cellular metabolism on chromatin dynamics and epigenetics. Nat. Cell Biol. 19, 1298–1306 (2017).
Ye, H. et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell 19, 23–37 (2016).
Hattori, A. et al. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. Nature 545, 500–504 (2017).
Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234 (2010).
Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17–30 (2011).
Losman, J. A. et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621–1625 (2013).
Wang, F. et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340, 622–626 (2013).
Warburg, O., Wind, F. & Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol. 8, 519–530 (1927).
Simsek, T. et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 7, 380–390 (2010).
Wang, Y. H. et al. Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell 158, 1309–1323 (2014).
Molina, J. R. et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med. 24, 1036–1046 (2018).
Konopleva, M. et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 6, 1106–1117 (2016).
Jones, C. L. et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell 35, 333–335 (2019).
Pollyea, D. A. et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat. Med. 24, 1859–1866 (2018). This study shows that venetoclax and azacitidine synergize to disrupt the TCA cycle and eradicate AML LSCs.
Sriskanthadevan, S. et al. AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. Blood 125, 2120–2130 (2015).
Chen, Y., Hu, Y., Zhang, H., Peng, C. & Li, S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat. Genet. 41, 783–792 (2009).
Chen, Y. et al. Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. J. Clin. Invest. 124, 3847–3862 (2014).
Saussele, S. et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 19, 747–757 (2018).
Clark, R. E. et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 6, E375–E383 (2019).
O’Hare, T. et al. AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401–412 (2009).
Cortes, J. E. et al. Ponatinib in refractory philadelphia chromosome-positive leukemias. N. Engl. J. Med. 367, 2075–2088 (2012).
Mian, A. A. et al. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. Leukemia 29, 1104–1114 (2015).
Wylie, A. A. et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543, 733–737 (2017).
Dierks, C. et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14, 238–249 (2008).
Irvine, D. A. et al. Deregulated Hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Sci. Rep. 6, 25476 (2016).
Shah, N. P. et al. Dasatinib plus Smoothened (SMO) inhibitor BMS-833923 in chronic myeloid leukemia (CML) with resistance or suboptimal response to a prior tyrosine kinase inhibitor (TKI): phase I study CA180323. Blood 124, 4539–4539 (2014).
Ottmann, O. et al. Smoothened (Smo) inhibitor Lde225 combined with nilotinib in patients with chronic myeloid leukemia (CML) resistant/intolerant (R/I) to at least 1 prior tyrosine kinase inhibitor: a phase 1b study. Haematologica 100, 62–63 (2015).
Cortes, J. E. et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 33, 379–389 (2019).
Savona, M. R. et al. Phase Ib study of glasdegib, a Hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS. Clin. Cancer Res. 24, 2294–2303 (2018).
Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561–566 (1996).
Jorgensen, H. G. et al. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin. Cancer Res. 12, 626–633 (2006).
Gallipoli, P. et al. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. Br. J. Haematol. 163, 674–676 (2013).
Milligan, D. W. et al. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood 107, 4614–4622 (2006).
Ossenkoppele, G. J. et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 103, 2908–2913 (2004).
Bhatia, R., Wayner, E. A., McGlave, P. B. & Verfaillie, C. M. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. J. Clin. Invest. 94, 384–391 (1994).
Hjorth-Hansen, H. et al. Safety and efficacy of the combination of pegylated interferon-alpha2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia 30, 1853–1860 (2016).
Rousselot, P. et al. Pioglitazone together with imatinib in chronic myeloid leukemia: a proof of concept study. Cancer 123, 1791–1799 (2017).
EU Clinical Trials Register. Clinicaltrialsregister.eu https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011675-79 (2009).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT02889003?term=NCT02889003&rank=1 (2016).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT02852486?term=NCT02852486&rank=1 (2016).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT02767063?term=NCT02767063&rank=1 (2016).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/study/NCT02730195?term=NCT02730195&rank=1 (2016).
Faber, K. et al. CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling. J. Clin. Invest. 123, 299–314 (2013).
Yen, K. et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 7, 478–493 (2017).
Shih, A. H. et al. Combination targeted therapy to disrupt aberrant oncogenic signaling and reverse epigenetic dysfunction in IDH2- and TET2-mutant acute myeloid leukemia. Cancer Discov. 7, 494–505 (2017).
DiNardo, C. D. et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N. Engl. J. Med. 378, 2386–2398 (2018). This paper reports on the findings of a phase I clinical trial in which the IDH1 inhibitor ivosidenib was evaluated in patients with AML with relapsed or refractory disease.
Stein, E. M. et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130, 722–731 (2017).
Amatangelo, M. D. et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood 130, 732–741 (2017).
Quek, L. et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat. Med. 24, 1167–1177 (2018). This paper describes the genetic evolution of AML clones in patients treated with the IDH2 inhibitor enasidenib.
Intlekofer, A. M. et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature 559, 125–129 (2018). This paper describes specific IDH1 and IDH2 mutations that drive resistance to ivosidenib and enasidenib in patients with AML.
Tsapogas, P., Mooney, C. J., Brown, G. & Rolink, A. The cytokine Flt3-ligand in normal and malignant hematopoiesis. Int. J. Mol. Sci. 18, E1115 (2017).
Stone, R. M. et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N. Engl. J. Med. 377, 454–464 (2017). This paper reports on the findings of a phase III clinical trial in which the FLT3 inhibitor midostaurin in combination with standard chemotherapy was evaluated in patients with AML with FLT3 mutations.
Swaminathan, M. et al. The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients (Pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Blood 130, 723–723 (2017).
Zhang, W. G. et al. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Clin. Cancer Res. 20, 2363–2374 (2014).
Stolzel, F. et al. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells. Ann. Hematol. 89, 653–662 (2010).
Sung, P. J., Sugita, M., Koblish, H., Perl, A. E. & Carroll, M. Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia. Blood Adv. 3, 1061–1072 (2019).
Sato, T. et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 117, 3286–3293 (2011).
Wei, A. H. et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J. Clin. Oncol. 37, 1277–1284 (2019).
DiNardo, C. D. et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133, 7–17 (2019).
Goff, D. J. et al. A pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 12, 316–328 (2013).
Ko, T. K., Chuah, C. T. H., Huang, J. W. J., Ng, K. P. & Ong, S. T. The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotarget 5, 9033–9038 (2014).
Carter, B. Z. et al. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci. Transl. Med. 8, 355ra117 (2016).
Baryawno, N. et al. A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia. Cell 177, 1915–1932.e16 (2019).
Nguyen, L. V. et al. Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells. Nature 528, 267–271 (2015).
Roeder, I. et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med. 12, 1181–1184 (2006).
Schepers, K., Campbell, T. B. & Passegue, E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell 16, 254–267 (2015).
Medyouf, H. The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications. Blood 129, 1617–1626 (2017).
Pittet, M. J. & Weissleder, R. Intravital imaging. Cell 147, 983–991 (2011).
Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
Godwin, C. D., Gale, R. P. & Walter, R. B. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia 31, 1855–1868 (2017).
Pizzitola, I. et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 28, 1596–1605 (2014).
Kenderian, S. S. et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 29, 1637–1647 (2015).
Lo-Coco, F. et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104, 1995–1999 (2004).
Walter, R. B., Appelbaum, F. R., Estey, E. H. & Bernstein, I. D. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 119, 6198–6208 (2012).
Borot, F. et al. Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies. Proc. Natl Acad. Sci. USA 116, 11978–11987 (2019).
Herrmann, H. et al. CD34+/CD38– stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. Haematologica 97, 219–226 (2012).
Jabbour, E. et al. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast-phase chronic myeloid leukemia. Clin. Lymphoma Myeloma Leuk. 12, 244–251 (2012).
Sadovnik, I. et al. Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: potential diagnostic value and functional implications. Exp. Hematol. 51, 17–24 (2017).
Touzet, L. et al. CD9 in acute myeloid leukemia: prognostic role and usefulness to target leukemic stem cells. Cancer. Med. 8, 1279–1288 (2019).
Sadovnik, I. et al. Identification of CD25 as STAT5-dependent growth regulator of leukemic stem cells in Ph+ CML. Clin. Cancer Res. 22, 2051–2061 (2016).
Saito, Y. et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci.Transl. Med. 2, 17ra9 (2010).
Valent, P. et al. DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia. Eur. J. Clin. Invest. 44, 1239–1245 (2014).
Jilani, I. et al. Differences in CD33 intensity between various myeloid neoplasms. Am. J. Clin. Pathol. 118, 560–566 (2002).
Chao, M. P., Weissman, I. L. & Majeti, R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol. 24, 225–232 (2012).
Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271–285 (2009).
Oehler, V. G. et al. CD52 expression in leukemic stem/progenitor cells. Blood 116, 2743 (2010).
de Boer, B. et al. Prospective isolation and characterization of genetically and functionally distinct AML subclones. Cancer Cell 34, 674–689.e8 (2018).
Greenlee-Wacker, M. C., Galvan, M. D. & Bohlson, S. S. CD93: recent advances and implications in disease. Curr. Drug Targets 13, 411–420 (2012).
Kinstrie, R. et al. CD93 is a novel biomarker of leukemia stem cells in chronic myeloid leukemia. Blood 126, 49–49 (2015).
Hosen, N. et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc. Natl Acad. Sci. USA 104, 11008–11013 (2007).
Chung, S. S. et al. CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Sci. Transl. Med. 9, eaaj2025 (2017).
Celik, H. et al. Discovery of first-in-class small molecule CD99 inhibitors for targeted therapy of Ewing sarcoma. Cancer Res. 77 (13 Suppl.), Abstract nr 1933 (2017).
van Rhenen, A. et al. The novel AML stem cell-associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110, 2659–2666 (2007).
Jaras, M. et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc. Natl Acad. Sci. USA 107, 16280–16285 (2010).
Askmyr, M. et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 121, 3709–3713 (2013).
Kikushige, Y. et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 7, 708–717 (2010).
Galton, D. A. G. Myleran in chronic myeloid leukaemia — results of treatment. Lancet 264, 208–213 (1953).
Fishbein, W. N., Carbone, P. P., Freireich, E., Misra, D. & Frei, E. Clinical trials of hydroxyurea in patients with cancer and leukemia. Clin. Pharmacol. Ther. 5, 574–580 (1964).
Doney, K. et al. Treatment of chronic granulocytic leukemia by chemotherapy, total-body irradiation and allogeneic bone-marrow transplantation. Exp. Hematol. 6, 738–747 (1978).
Talpaz, M., Mccredie, K. B., Mavligit, G. M. & Gutterman, J. U. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62, 689–692 (1983).
Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399–401 (2004).
Weisberg, E. et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129–141 (2005).
Puttini, M. et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 66, 11314–11322 (2006).
Rodriguez, V. et al. Pomp combination chemotherapy of adult acute leukemia. Cancer 32, 69–75 (1973).
Lichtman, M. A. A historical perspective on the development of the cytarabine (7 days) and daunorubicin (3 days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. Blood Cells Mol. Dis. 50, 119–130 (2013).
Thomas, E. D. et al. One hundred patients with acute-leukemia treated by chemotherapy, total-body irradiation, and allogeneic marrow transplantation. Blood 49, 511–533 (1977).
Weisberg, E. et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1, 433–443 (2002).
Lu, C. & Thompson, C. B. Metabolic regulation of epigenetics. Cell Metab. 16, 9–17 (2012).
Maddocks, O. D. K., Labuschagne, C. F., Adams, P. D. & Vousden, K. H. Serine metabolism supports the methionine cycle and DNA/RNA methylation through de novo ATP synthesis in cancer cells. Mol. Cell 61, 210–221 (2016).
Gallipoli, P., Giotopoulos, G. & Huntly, B. J. P. Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. Ther. Adv. Hematol. 6, 103–119 (2015).
Gross, S. et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339–344 (2010).
Eide, C. A. et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell 36, 431–443.e5 (2019). This study provides a rationale for using asciminib in combination with ponatinib to treat patients with CML that are resistant to current TKI therapy due to BCR–ABL1 compound mutations.
Gallipoli, P. et al. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood 124, 1492–1501 (2014).
Lim, S. et al. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc. Natl Acad. Sci. USA 110, E2298–E2307 (2013).
Essers, M. A. G. et al. IFNα activates dormant haematopoietic stem cells in vivo. Nature 458, 904–908 (2009).
Chen, M. et al. Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex. Oncotarget 8, 43662–43677 (2017).
Pemovska, T. et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 519, 102–105 (2015).
Riether, C., Gschwend, T., Huguenin, A. L., Schurch, C. M. & Ochsenbein, A. F. Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells. Leukemia 29, 1781–1785 (2015).
Turhan, A. G. et al. Vitamin D3 analog inecalcitol synergizes with tyrosine kinase inhibitors (TKI) and selectively inhibit the growth of chronic myeloid leukemia (CML) progenitors: development of a clinically applicable leukemic stem cell targeting strategy. Cancer Res. 75, 3981–3981 (2015).
D.V. and M.C. are jointly funded by Bloodwise (Ref. 14033) and the Stand Up To Cancer campaign for Cancer Research UK (Ref. C55731/A24896). G.V.H. is funded by the Kay Kendall Research Fund (Ref. KKL1069), the Howat Foundation and Bloodwise (Ref. 18006).
The authors declare no competing interests.
Dedication: The authors dedicate this Review to our absent colleague Tessa Laurie Holyoake, whose untimely passing in 2017 cut short the life of a brilliant clinician and scientist. Her discovery of the quiescent CML LSC in 1999, her dedication to the preclinical study of LSCs in the years that followed and her commitment to cure CML, paved the way for many of the scientific discoveries discussed here.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Cancer Research UK: https://www.cancerresearchuk.org/
Surveillance, Epidemiology, and End Results Program: https://seer.cancer.gov/
- Philadelphia chromosome
(Ph). The chromosomal abnormality characteristic of CML cells that arises from a reciprocal translocation between chromosomes 9 and 22.
- Relative survival
The percentage survival of individuals with leukaemia after taking into account death rates of individuals without leukaemia.
A population of cells characterized by markers expressed on the cell surface as determined by flow cytometry.
The relative proportions of human to mouse cells that result when human cells are engrafted into the bone marrow of immunocompromised mice.
- Clonal haematopoiesis of indeterminant potential
(CHIP). A process that occurs in some older individuals whereby DNA mutations in haematopoietic stem cells result in the accumulation of clonally expanded populations of haematopoietic cells.
Multipotent precursor cells that can give rise to both haematopoietic stem cells and enthothelial cells.
- Oxidative phosphorylation
(OXPHOS). The mitochondrial process in which electrons are transferred from NADH or FADH2 to oxygen (O2) through a series of carriers and protein complexes to produce ATP from ADP and phosphate.
- BH3 mimetic
One of a class of compounds that bind to a hydrophobic groove found in antiapoptotic proteins and prevents them from binding to the BH3 domain of the BCL-2 family of proteins.
About this article
Cite this article
Vetrie, D., Helgason, G.V. & Copland, M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer 20, 158–173 (2020). https://doi.org/10.1038/s41568-019-0230-9
A mitophagy inhibitor targeting p62 attenuates the leukemia-initiation potential of acute myeloid leukemia cells
Cancer Letters (2021)
Trends in Genetics (2021)
American Journal of Physiology-Cell Physiology (2021)
Nature Reviews Cancer (2021)